Stockreport

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc.  (AGLE) 
Last aeglea biotherapeutics, inc. earnings: 8/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aegleabio.com/investor-overview
PDF Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas, June 03, 2019 ( [Read more]